GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » Issuance of Debt

Oncolytics Biotech (TSX:ONC) Issuance of Debt : C$0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Oncolytics Biotech Issuance of Debt?

Oncolytics Biotech's Issuance of Debt for the three months ended in Sep. 2024 was C$0.00 Mil.

Oncolytics Biotech's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil.

Oncolytics Biotech Issuance of Debt Historical Data

The historical data trend for Oncolytics Biotech's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Issuance of Debt Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncolytics Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oncolytics Biotech Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolytics Biotech Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » Issuance of Debt
Comparable Companies
TSXV:COV XCNQ:METX TSX:MSCL TSX:MDNA XCNQ:ACOG TSXV:ARCH TSX:TH TSX:SVA XCNQ:GLAB TSXV:NRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
ONCY:USA
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Website
https://www.oncolyticsbiotech.com
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
Executives
Angela Frances Holtham Director
Deborah Brown Director
Bernd Robert Seizinger Director
Matthew Coffey Director, Senior Officer
Kirk Look Senior Officer

Oncolytics Biotech Headlines

No Headlines